New Federal Contractors — March 31, 2026

Four contracts totaling $2.06B to Raytheon, Lockheed, TRAX, and Caltech underscore long-term (to 2029) funding for space vehicles, instruments, and logistics.

HII and Sevenson win $626M in GSA/DoD task orders for engineering and remediation, with options pushing potential value over $1.1B through 2032.

$256M HHS award for botulism antitoxin extends to potential 2029, with 73% ($188M) already outlayed.

Long performance periods (8-18 years) across 7/8 contracts heighten funding cliffs and cost overrun exposure in cost-plus structures.

Award fee mechanisms in 5 contracts tie ~$2.5B payments to NASA/DoD performance evals; foreign ownership in Emergent adds sourcing scrutiny.

NASA concentration (67%) exposes portfolios to space budget volatility; nearing-end contracts like TRAX risk non-renewal.

$627M in unexercised options across contracts could boost RTX, HII, TRAX by 10-50% if funded.

Pattern of reissues/extensions (TRAX, Raytheon) signals follow-on potential in NASA space and DoD remediation.

Low outlays (e.g., Raytheon $316M/1.22B, Lockheed $44M/301M) indicate upside as funds deploy over 3-6 years.

67% of value in long-term space vehicle/instrument contracts highlights multi-year R&D and ops funding.

DoD/GSA awards to HII/Sevenson total $626M+options for engineering/remediation through 2032.

{"entity"=>"RTX/Raytheon", "reason"=>"Largest award ($1.22B) with $940M remaining obligation to 2029.", "trigger"=>"VIRS milestone funding or follow-on NASA wins"}

{"entity"=>"HII Mission Technologies", "reason"=>"$446M obligation with $509M options under GSA FAS.", "trigger"=>"post-2025 extensions or new task orders"}

{"entity"=>"NASA Goddard Space Flight Center", "reason"=>"Hub for 50%+ of value ($2B across 4 contracts).", "trigger"=>"FY2027 budget allocation shifts"}